Therapeutics Acquisition Corporation (TXAC)
| Market Cap | 232.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 14.04M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Aug 6, 2020 |
| Last Price | $12.96 |
| Previous Close | $12.96 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 12.21 - 13.10 |
| Day's Volume | 0 |
| 52-Week Range | 11.11 - 21.44 |
News
These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?
Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.
BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp. (Nasdaq: TXAC) (the “Company”) announced today that on July 10, 2020 it closed its initial public offering of 13,570,000 shares of Class...
The special purpose acquisition company is sponsored by RA Capital Management.
About TXAC
Therapeutics Acquisition focuses on merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify and acquire a business focusing on the healthcare industry. The company was founded in 2020 and is based in Boston, Massachusetts.
| Industry Shell Companies | IPO Date Jul 8, 2020 |
| CEO Peter Kolchinsky | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol TXAC |